In Vitro Fertilization (IVF) Market - Forecasts from 2024 to 2029

The in vitro fertilization (IVF) market is anticipated to expand at a CAGR of 9.37% over the forecast period, from US$24.52 billion in 2022 to a total market value of US$45.895 billion by 2029.

A sophisticated set of techniques known as in vitro fertilization (IVF) is used to cure genetic or reproductive issues and aid in child conception. Patients with blocked or damaged fallopian tubes, male factor infertility, women with ovulation disorders, premature ovarian failure, uterine fibroids, excised fallopian tubes, and unexplained infertility are among the infertility conditions that can be treated with IVF. The increase may be attributable to the increased rates of male and female infertility brought on by lifestyle changes. Growing public understanding and acceptance of infertility treatment will encourage the use of in vitro fertilization (IVF) methods, which will accelerate the development of the in vitro fertilization (IVF) market.

However, the main factor limiting the potential market for in vitro fertilization (IVF) is the cost of the treatments, which is well-known around the world.

MARKET DRIVERS:

The increasing number of median age of first-time mothers is anticipated to drive the market growth

Because more women are choosing careers over family planning and later marriages than in the past, the median age of first-time mothers has increased significantly as a result of the expanding human population. The effective use of contraceptives has also significantly influenced the median age of first-time mothers, and this is anticipated to significantly fuel the expansion of the in vitro fertilization (IVF) market.

The segment of sperm separation systems is expected to surge the growth of the market

Sperm separation systems are crucial in assisted reproductive technologies (ART) like in vitro fertilization (IVF) and artificial insemination, providing purified samples for subsequent procedures. The market growth is driven by companies developing novel devices for ART procedures in fertility clinics and obstetrician-gynaecologist practices. The increasing use of advanced technology, such as sperm syringes, in selecting high-quality sperm is expected to fuel the segment growth.

By End-User

By body part, the In-Vitro Fertilization Market is segmented as Fertility Clinics Hospitals & Research Centers. The Clinical research centers are anticipated to have the fastest growth owing to the majority of research on fertility problems and their possible treatment.

By Geography

Geographically, the In-Vitro Fertilization Market is segmented as North America, South America, Europe, the Middle East and Africa, and Asia Pacific. The greatest market share corresponds to the Asia-Pacific region, which has a huge population base, rising IVF treatment awareness, low IVF treatment prices, and an increase in the population of infertile people.

Key Developments:

• May 2023- AIVF and Genea Biomedx have announced the launch of an integrated system aimed at revolutionizing the IVF market. The system combines Genea Biomedx's Geri time-lapse incubator with AIVF's EMA AI platform, offering personalized IVF care at a reduced cost. This system will reduce patient costs while increasing clinic revenues as efficiency increases and patient access improves. The combination of AIVF's Geri time-lapse incubator and Genea Biomedx's advanced EM AI platform will provide widespread access to personalized, optimized IVF care.
• June 2022- FUJIFILM Irvine Scientific, a global leader in cell culture media and assisted reproductive technologies, has obtained an exclusive license to intellectual property related to artificial intelligence (AI). Researchers from Massachusetts General Hospital and Brigham and Women's Hospital collaborated to develop and patent the method. FUJIFILM Irvine Scientific plans to offer a non-exclusive license of the technology to businesses, seeking agreements globally. The image-based solution integrates easily into current IVF operations without capital expenditure, offering laboratories a simpler and more affordable entry point for integrating AI and image analysis into their workflows.

Product Offerings:

• Continuous Single Culture-NX Complete: Continuous Single Culture-NX Complete (CSCM-NXC) is a low-lactate, single-step culture medium with a track record in the therapeutic setting for enhancing blastocyst development. The CSCM-NXC is intended for fertilization and embryo culture up to days 5 and 6. This medium is designed to be utilized in an ongoing culture system without dish replacement or medium replacement. Removing unneeded stress, it supports the maintenance of efficient metabolic rates. Pre-supplemented with HSA, with a final total protein concentration of 5 mg/mL, is the available option.
• FreyGen ALF: FreyGen ALF is a line of incubators by IVFtech ApS built on an extensive study that provided the knowledge required to design the ideal "simple to manage - best results" incubators tailored to physicians' requirements. Oocytes and embryos can be developed and incubated in the ideal environment with the help of the FreyGen line of incubators. Benchtop incubators also referred to as dry incubators, are what are used in incubators. The fact that the trays are also removable makes it so much simpler to clean them and carry dishes to a workspace on a warm plate. It contains a data logger and a remote alert system so the physician can keep track of the incubator's performance.

Segmentation

By Cycle Type

• Fresh IVF Cycle
• Thawed IVF Cycle
• Donor Egg IVF Cycles

By End-User

• Fertility Clinics
• Hospitals and research centers

By Geography

• North America
• USA
• Mexico
• Canada
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• India
• China
• Japan
• South Korea
• Taiwan
• Thailand
• Indonesia
• Others